Form 4: REGENXBIO Chief Medical Officer Steve Pakola Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
REGENXBIO's Chief Medical Officer, Steve Pakola, exercised stock options and sold shares of common stock on March 5, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 5, 2024, Steve Pakola, Chief Medical Officer of REGENXBIO Inc., executed a transaction involving the company's common stock.
- Pakola exercised stock options to acquire 12,878 shares at a price of $22.25 per share.
- Simultaneously, Pakola sold 12,878 shares at a price of $28.36 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Pakola directly owns 107,192 shares of REGENXBIO common stock and holds options for 31,277 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.
Industry Context
This is a routine disclosure of insider transactions. It is common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 04/15/2019 | Date of Power of Attorney execution. |
| 01/03/2024 | 25% of stock options vested. |
| 03/05/2024 | Date of stock option exercise and sale. |
| 03/07/2024 | Date of signature for the report. |
| 01/03/2033 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.